pharmaphorum

JUNE 30, 2021

Just a few months after starting clinical trials of its nasal spray vaccine for COVID-19, US biotech Altimmune is abandoning the project, saying that it generated weaker than expected immune responses in a phase 1 trial. .

Vaccination 98

Vaccination Vaccine Trials Immune Response 98

The Pharma Data

OCTOBER 20, 2020

” Mr. Bliss joins TLC following interim roles in cellular therapy, drug delivery and combination therapy where he led efforts to confirm research outcomes and partner the various technologies. Earlier in his career, he ran business-development functions at Amgen and Baxter.

Licensing 40

Licensing Licensing Drug Delivery Business Development 40

Roots Analysis

MARCH 3, 2022

Since the approval of Soliris® in 2007, an anti-C5 antibody, the field of complement drug discovery has gained significant attention. Broad Clinical Trial Landscape. Currently, nine complement therapeutics are commercially available, while around 190 molecules are under development for various disease indications.

Drug Delivery Systems 52

Drug Delivery Systems Marketing Immune Response Dermatology 52

The Pharma Data

JANUARY 17, 2021

Darzalex Faspro is the only CD38-directed antibody that has been approved for subcutaneous injection for multiple myeloma, and now AL amyloidosis. It is co-formulated with recombinant hyaluronidase PH20 (rHuPH20), Halozyme’s ENHANZE drug delivery technology. AL amyloidosis affects about 4,500 people in the U.S.

FDA Approval 52

FDA Approval Drug Delivery Doctors Doctor 52

Delveinsight

JANUARY 22, 2021

Thrombocytopenia pipeline possesses potential drugs in mid-stage developments to be approved shortly. Efgartigimod (ARGX-113) is an investigational therapy for IgG-mediated autoimmune diseases, designed to leverage the natural interaction between IgG antibodies and the recycling receptor FcRn.

Marketing 65

Marketing Drugs Antibody Compliance 65

XTalks

OCTOBER 27, 2021

Genentech’s ocular implant drug delivery system for treatment of macular degeneration has received approval from the US Food and Drug Administration (FDA). Susvimo delivers ranibizumab via a port delivery system into a surgically placed implant in the eye, allowing for continuous delivery of the drug.

Drug Delivery Systems 104

Drug Delivery Systems Drug Delivery FDA Approval Drugs 104

The Pharma Data

JUNE 26, 2021

The safety profile of PDS in the clinical trial setting is well understood and will continue to be closely monitored. The safety profile of PDS in the clinical trial setting is well understood and will continue to be closely monitored. Faricimab is the first investigational bispecific antibody designed for the eye.

Drug Delivery 52

Drug Delivery Clinical Trials Clinical Trials Medicine 52

XTalks

AUGUST 30, 2022

One of the biggest challenges with developing therapies to treat CNS disorders is the delivery of systemically administered investigational products (IPs) to the brain, which is limited by the blood-brain barrier. Some methods of direct CNS administration include intrathecal, intraparenchymal and intracerebroventricular (ICV) delivery.

Trials 83

Trials Drug Delivery Drugs Gene 83

The Pharma Data

APRIL 12, 2023

4-7 Additionally, phase I data for an investigational anti-interleukin-6 (IL-6) treatment in uveitic macular edema (UME), to be presented for the first time, suggest the monoclonal antibody may improve visual acuity in patients with UME. 1 4 About Vabysmo ® ( faricimab ) Vabysmo is the first bispecific antibody approved for the eye.

Antibody 40

Antibody In-Vitro Development Trials 40

The Pharma Data

AUGUST 31, 2021

S ites and Burden of Metastases and Long-Term Outcomes in TITAN Patients (moderated poster session) : Assessment of relationships between the number and location of metastases and oncological outcomes in 1,052 patients with metastatic castration-sensitive prostate cancer (mCSPC) enrolled in the TITAN trial (Abstract #MP24-08). About TAR-200.

Drug Delivery Systems 52

Drug Delivery Systems Drug Delivery Trials Drugs 52

The Pharma Data

JANUARY 15, 2021

Darzalex Faspro® is not indicated and is not recommended for the treatment of patients with light chain (AL) amyloidosis who have NYHA Class IIIB or Class IV cardiac disease or Mayo Stage IIIB outside of controlled clinical trials. About Darzalex Faspro® In August 2012, Janssen Biotech, Inc.

FDA Approval 52

FDA Approval Production Research Doctors 52

Delveinsight

NOVEMBER 29, 2020

Therapies such as dexamethasone drug delivery system and vascular endothelial growth factor inhibitors have already pierced deeper into the market. Brolucizumab is a humanized single-chain antibody fragment (scFv). The company has plans to initiate new trials for the product however not until the second half of 2021.

Marketing 52

Marketing Pharma Companies Drug Delivery Clinical Trials 52

Delveinsight

JULY 30, 2021

However, the Crohn’s disease market space experienced strides of research and developments imbibed with continuous innovation in terms of drug delivery platforms, MoAs, and RoAs with an end goal to minimize the numbers of patients experiencing no-response from the treatment.

Marketing 74

Marketing Drug Delivery Development Clinical Trials 74

The Pharma Data

JANUARY 17, 2021

The primary endpoint of this trial is to evaluate patients for complete histological clearance of the tumor cells within the treated BCC lesion with secondary endpoints, evaluating subjects for investigational product treatment related adverse events, as well as serious adverse events, and cutaneous skin reactions. Chief Medical Officer.

Gene Expression 52

Gene Expression Trials Production Development 52